ABVC BioPharma, Inc. Press Release


ABVC BioPharma Receives $450,000 in Licensing Payments from OncoX BioPharma in Q3 2025
Aug 29, 2025 19:39 JST
ABVC BioPharma, Inc. (NASDAQ: ABVC) (ABVC or the Company), a clinical-stage biopharmaceutical company developing innovative therapies in oncology, ophthalmology, and central nervous system (CNS) disorders, today announced that its partner OncoX BioPharma has delivered $450,000 in licensing payments in the third quarter of 2025 , including $350,000 received in August. These
More info..

Latest Release


More Latest Release >>